Abstract 556P
Background
Iruplinalkib (WX-0593) is a novel ALK TKI. Here, we report the results from the phase 1 study on efficacy and safety of iruplinalkib for ALK-positive NSCLC patients who received prior second-generation ALK TKIs.
Methods
ALK- or ROS1-positive advanced NSCLC patients were enrolled in the phase 1 study. In the dose-escalation phase, patients received iruplinalkib 30–300 mg orally once daily. In the dose-expansion phase, patients received iruplinalkib 120 or 180 mg orally once daily with or without a 7-day lead-in at 60 mg. Efficacy and safety were assessed by investigators. ALK-positive patients previously treated with second-generation ALK TKIs were included in this analysis.
Results
Totally, 153 patients were enrolled in the phase 1 study, among which 11 patients (five [45%] in the dose-escalation phase and six [55%] in the dose-expansion phase) who received prior second-generation ALK TKIs were eligible for this analysis. Median age was 52 years old. Six (55%) were male. There were one (9%), four (36%), four (36%) and two (18%) patients in 90 mg, 120 mg, 180 mg, and 240 mg orally once daily group of iruplinalkib, respectively. Brain metastasis and prior treatment were summarized in the table. As of the data cut-off date on July 31, 2023, median follow-up was 53.3 months. Six patients (55%, 95% confidence interval [CI] 23%–84%) had objective response. Median progression-free survival (PFS) was 8.1 months (95% CI 2.2–30.2). Nine (82%) and three (27%) patients experienced any grade and grade ≥ 3 treatment-related adverse event (TRAE), respectively. Other endpoints were shown in the table. Table: 556P
Parameters | Results (n=11) |
Baseline brain metastasis | 7 (64%) |
Prior ALK TKIs | |
Crizotinib + second-generation | 9 (82%) |
Second-generation only | 2 (18%) |
Detailed second-generation ALK TKI | |
Ensartinib | 5 (45%) |
Conteltinib | 4 (36%) |
Ceritinib | 1 (9%) |
Brigatinib | 1 (9%) |
Prior chemotherapy | 9 (82%) |
Best objective response | |
Partial response | 6 (55%) |
Stable disease | 4 (36%) |
Progressive disease | 1 (9%) |
Objective response | 6 (55%, 95% CI 23%–83%) |
Disease control | 10 (91%, 95% CI 59%–100%) |
PFS event | 9 (82%) |
Median PFS, months | 8.1 (95% CI 2.2–30.2) |
Any grade TRAE | 9 (82%) |
Grade ≥ 3 TRAE | 3 (27%) |
TRAE leading to dose interruption/reduction/discontinuation | 2 (18%)/0/0 |
Conclusions
Iruplinalkib demonstrated promising efficacy and acceptable toxicity in ALK-positive advanced NSCLC patients previously treated with second-generation ALK TKIs.
Clinical trial identification
NCT03389815.
Editorial acknowledgement
We thank Yunjie Yu (Qilu Pharmaceutical Co., Ltd., Jinan, China) for providing medical writing support.
Legal entity responsible for the study
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs.
Funding
Qilu Pharmaceutical Co., Ltd. (Jinan, China) and China National Major Project for New Drug Innovation (2017ZX09304015).
Disclosure
M. Wang, M. Si, Y. Sang, X. Kang: Financial Interests, Personal, Full or part-time Employment: Qilu Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract